Abstract

Vanadate can be bioequivalent to phosphate and replace it in cellular metabolism. The detection of insulin-like activity has spurred interest in the development of oral anti-diabetic drugs containing vanadium. We collected and evaluated a vast toxicity data set and discussed molecular aspects related to insulin-mimetic effects of vanadium complexes.

Keywords: vanadium, anti-diabetic, insulin-mimetic, phospho-mimetic, ptp-1b, toxicity, molecular design